Opinion on R&D in United Kingdom

Select information type

Refine your search

search
Search tips

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Heinz: beans beat broccoli (sometimes)

The British Dietetic Association found that several of Heinz' canned foods help consumers to consume five portions of fruit and vegetables per day. But although Heinz is set to capitalize on the research, rebranding dozens of its products to emphasize the health benefits, it may keep some of the BDA's other findings away from its labels.

Published By Datamonitor
18 Apr 2002
CommentWire
CommentWire

Liberate: a Two Way bet on enhanced programming

Liberate 1.2 includes enhanced programming software from Two Way TV, allowing TV operators to link interactive services directly to scheduled programs. Since enhanced programming is likely to be a major driver of iTV usage, middleware vendors must either develop proprietary solutions in this area, or rapidly integrate third party technologies to avoid delays to roll-out.

Published By Datamonitor
24 Apr 2002
CommentWire
CommentWire

Chickenpox: vaccination could do more harm than good

The UK research shows that, by cutting adults' exposure to the virus that causes both chickenpox and shingles, vaccination programs may do more harm than good. This is bad news for GSK, which is seeking UK approval for its chickenpox vaccine. However, it could be good news for products seeking to protect adults against shingles.

Published By Datamonitor
07 May 2002
CommentWire
CommentWire

Cytotoxics: new regime out on a limb

By isolating the cancerous limb from the rest of the circulatory system, ILI allows doctors to step up chemotherapy doses significantly. ILI is also far less invasive than similar procedures such as ILP. The combination of greater efficacy and lower cost is likely to drive strong uptake among physicians, in turn boosting the usage of cytotoxic therapies.

Published By Datamonitor
13 May 2002
CommentWire
CommentWire

Novartis: Glivec leaves Brits unconvinced

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, NICE has decided to limit its use in CML patients to the accelerated phase only. The watchdog's reason was the lack of cost-effective data, showing that pharma companies need to ensure their clinical trials highlight this factor convincingly.

Published By Datamonitor
15 May 2002
CommentWire
CommentWire

AstraZeneca: only a short-term setback for Arimidex

Trial results showed a slight advantage for Arimidex over tamoxifen in treating early breast cancer in post-menopausal women. However, ASCO has advised caution in replacing tamoxifen with AstraZeneca's drug. Although this verdict will hold sales back in the short term, there is still huge long-term potential for Arimidex as the preferred breast cancer therapy.

Published By Datamonitor
20 May 2002
Expert View
Expert View

Ironing out the Glivec-glitch

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, the National Institute of Clinical Excellence has decided to limit its use in chronic myeloid leukemia patients to the accelerated phase only, due to the lack of cost-effective data. Datamonitor's Oliver Luft investigates Glivec's costly delay and asks what can be done to prevent future hold-ups.

Published By Datamonitor
24 May 2002
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
Expert View
Expert View

MMR: controversy puts the Government under pressure

After hearing about a possible link with autism many parents are refusing to allow doctors to give their children the MMR vaccine. As a result, the number of measles cases in the UK has risen dramatically. Datamonitor's Oliver Luft outlines the series of events that led to the current crisis and investigates whether or not the government can encourage more parents to take up the combined vaccine.

Published By Datamonitor
12 Jul 2002
CommentWire
CommentWire

HRT: no new prescriptions

After the Prempro arm of the Women's Health Initiative trial was stopped last week, the UK's Department of Health in the UK said that no new prescriptions should be made for HRT as a preventative treatment for cardiovascular disease. The decision will hit the use of HRT in the UK, potentially driving uptake of Eli Lilly's Evista.

Published By Datamonitor
15 Jul 2002

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.